[Status of adriamycin in cancer therapy].
Adriamycin is a cytotoxic drug with a broader spectrum of activity against various cancers than older drugs. Therefore there are numerous indications for the application of adriamycin in monotherapy and polychemotherapy. Besides other side effects which are common to all cytotoxic drugs adriamycin induces heart failure when applied in doses of 500 mg/sqm body surface. Cardiotoxicity may be reduced by weekly application instead of 3 week intervals and by concommittant application of calcium antagonists (verapamil). It seems that the potential value of adriamycin in cancer chemotherapy is as yet not fully explored.
D000505:Alopecia / Q000139:chemically induced; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy; D002283:Carcinoma, Bronchogenic / Q000188:drug therapy; D004317:Doxorubicin / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006321:Heart / Q000187:drug effects; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy; D008297:Male; D009369:Neoplasms / Q000188:drug therapy*; D013280:Stomatitis / Q000139:chemically induced
D000970:Antineoplastic Agents; D004317:Doxorubicin
Zum Stand der Krebstherapie mit Adriamycin.